Characterization and quantitation of primitive hematopoietic progenitor cells present in peripheral blood autografts

J. Tong, R. Hoffman, S. Siena, Edward Srour, M. Bregni, A. M. Gianni

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

In this report, we assess the content of primitive hematopoietic progenitor cells (HPC) that circulate transiently in the peripheral blood (PB) of cancer patients (group A) who received a PB stem-cell-mobilizing regimen that included high-dose chemotherapy (HD-CTX) of 7 g/m2 cyclophosphamide followed by a combination of recombinant hematopoietic growth factors (C-HGF), including either interleukin-3 (IL-3) plus granulocyte-colony stimulating factor (G-CSF), IL-3 plus granulocyte-macrophage colony-stimulating factor (GM-CSF), or a recombinant GM-CSF/IL-3 fusion protein (PIXY-321). These data were compared to the HPC content of PB obtained from a similar group of cancer patients that had not received such a mobilization regimen (group B). Monoclonal antibody staining and fluorescence-activated cell sorting (FACS) were used to identify and isolate cell populations enriched for more differentiated HPC (CD34+HLA-DR+) and more primitive HPC (CD34+HLA-DR-). The content of CD34+HLA-DR+ and CD34+HLA-DR- cells in the PB of group A patients was significantly greater than that observed in the PB of group B patients. In addition, HD-CTX plus C-HGF mobilization resulted in the appearance of greater numbers of PB colony-forming units - granulocyte/macrophage, -granulocyte/erythroid/macrophage/megakaryocyte, and -megakaryocyte (CFU-GM, CFU-GEMM, and CFU-Mk), and burst-forming units-erythroid and megakaryocyte (BFU-E and BFU-Mk) than those observed in the PB of group B patients (p <0.01). CD34+HLA-DR- cells isolated from the PB of group A patients were capable of initiating long-term hematopoiesis in vitro, which persisted for 10 weeks, while CD34+HLA-DR- cells obtained from the PB of group B patients were capable of sustaining long-term hematopoiesis in vitro for only 4 weeks. As determined by a limiting dilution analysis of group A PB CD34+HLA-DR- cells, the frequency of cells capable of giving rise to hematopoietic progenitor cells (pre-CFC) after 2 weeks in liquid culture was 4.3% (range 1.0-8.3%). Pre-CFC constituted 0.01% (range 0.001-0.02%) of group A PB mononuclear cells, and 151 pre-CFC were calculated to be present in 1 mL mobilized PB (range 20-310/mL). These results suggest that peripheral blood mononuclear cells (PBMC) collected by leukapheresis following HD-CTX plus C-HGF mobilization contain not only differentiated HPC but also more primitive HPC.

Original languageEnglish (US)
Pages (from-to)1016-1024
Number of pages9
JournalExperimental Hematology
Volume22
Issue number10
StatePublished - 1994
Externally publishedYes

Fingerprint

Autografts
HLA-DR Antigens
Hematopoietic Stem Cells
Blood Group Antigens
Megakaryocytes
Interleukin-3
Myeloid Progenitor Cells
Intercellular Signaling Peptides and Proteins
Erythroid Precursor Cells
Hematopoiesis
Granulocyte-Macrophage Colony-Stimulating Factor
Blood Cells
Leukapheresis
Granulocyte-Macrophage Progenitor Cells
Granulocyte Colony-Stimulating Factor
Granulocytes
Cyclophosphamide
Neoplasms
Flow Cytometry
Macrophages

Keywords

  • Hematopoietic stem cells
  • Peripheral blood grafts

ASJC Scopus subject areas

  • Cancer Research
  • Cell Biology
  • Genetics
  • Hematology
  • Oncology
  • Transplantation

Cite this

Characterization and quantitation of primitive hematopoietic progenitor cells present in peripheral blood autografts. / Tong, J.; Hoffman, R.; Siena, S.; Srour, Edward; Bregni, M.; Gianni, A. M.

In: Experimental Hematology, Vol. 22, No. 10, 1994, p. 1016-1024.

Research output: Contribution to journalArticle

Tong, J. ; Hoffman, R. ; Siena, S. ; Srour, Edward ; Bregni, M. ; Gianni, A. M. / Characterization and quantitation of primitive hematopoietic progenitor cells present in peripheral blood autografts. In: Experimental Hematology. 1994 ; Vol. 22, No. 10. pp. 1016-1024.
@article{b365b901368d49ec8cfa10e75da66e36,
title = "Characterization and quantitation of primitive hematopoietic progenitor cells present in peripheral blood autografts",
abstract = "In this report, we assess the content of primitive hematopoietic progenitor cells (HPC) that circulate transiently in the peripheral blood (PB) of cancer patients (group A) who received a PB stem-cell-mobilizing regimen that included high-dose chemotherapy (HD-CTX) of 7 g/m2 cyclophosphamide followed by a combination of recombinant hematopoietic growth factors (C-HGF), including either interleukin-3 (IL-3) plus granulocyte-colony stimulating factor (G-CSF), IL-3 plus granulocyte-macrophage colony-stimulating factor (GM-CSF), or a recombinant GM-CSF/IL-3 fusion protein (PIXY-321). These data were compared to the HPC content of PB obtained from a similar group of cancer patients that had not received such a mobilization regimen (group B). Monoclonal antibody staining and fluorescence-activated cell sorting (FACS) were used to identify and isolate cell populations enriched for more differentiated HPC (CD34+HLA-DR+) and more primitive HPC (CD34+HLA-DR-). The content of CD34+HLA-DR+ and CD34+HLA-DR- cells in the PB of group A patients was significantly greater than that observed in the PB of group B patients. In addition, HD-CTX plus C-HGF mobilization resulted in the appearance of greater numbers of PB colony-forming units - granulocyte/macrophage, -granulocyte/erythroid/macrophage/megakaryocyte, and -megakaryocyte (CFU-GM, CFU-GEMM, and CFU-Mk), and burst-forming units-erythroid and megakaryocyte (BFU-E and BFU-Mk) than those observed in the PB of group B patients (p <0.01). CD34+HLA-DR- cells isolated from the PB of group A patients were capable of initiating long-term hematopoiesis in vitro, which persisted for 10 weeks, while CD34+HLA-DR- cells obtained from the PB of group B patients were capable of sustaining long-term hematopoiesis in vitro for only 4 weeks. As determined by a limiting dilution analysis of group A PB CD34+HLA-DR- cells, the frequency of cells capable of giving rise to hematopoietic progenitor cells (pre-CFC) after 2 weeks in liquid culture was 4.3{\%} (range 1.0-8.3{\%}). Pre-CFC constituted 0.01{\%} (range 0.001-0.02{\%}) of group A PB mononuclear cells, and 151 pre-CFC were calculated to be present in 1 mL mobilized PB (range 20-310/mL). These results suggest that peripheral blood mononuclear cells (PBMC) collected by leukapheresis following HD-CTX plus C-HGF mobilization contain not only differentiated HPC but also more primitive HPC.",
keywords = "Hematopoietic stem cells, Peripheral blood grafts",
author = "J. Tong and R. Hoffman and S. Siena and Edward Srour and M. Bregni and Gianni, {A. M.}",
year = "1994",
language = "English (US)",
volume = "22",
pages = "1016--1024",
journal = "Experimental Hematology",
issn = "0301-472X",
publisher = "Elsevier Inc.",
number = "10",

}

TY - JOUR

T1 - Characterization and quantitation of primitive hematopoietic progenitor cells present in peripheral blood autografts

AU - Tong, J.

AU - Hoffman, R.

AU - Siena, S.

AU - Srour, Edward

AU - Bregni, M.

AU - Gianni, A. M.

PY - 1994

Y1 - 1994

N2 - In this report, we assess the content of primitive hematopoietic progenitor cells (HPC) that circulate transiently in the peripheral blood (PB) of cancer patients (group A) who received a PB stem-cell-mobilizing regimen that included high-dose chemotherapy (HD-CTX) of 7 g/m2 cyclophosphamide followed by a combination of recombinant hematopoietic growth factors (C-HGF), including either interleukin-3 (IL-3) plus granulocyte-colony stimulating factor (G-CSF), IL-3 plus granulocyte-macrophage colony-stimulating factor (GM-CSF), or a recombinant GM-CSF/IL-3 fusion protein (PIXY-321). These data were compared to the HPC content of PB obtained from a similar group of cancer patients that had not received such a mobilization regimen (group B). Monoclonal antibody staining and fluorescence-activated cell sorting (FACS) were used to identify and isolate cell populations enriched for more differentiated HPC (CD34+HLA-DR+) and more primitive HPC (CD34+HLA-DR-). The content of CD34+HLA-DR+ and CD34+HLA-DR- cells in the PB of group A patients was significantly greater than that observed in the PB of group B patients. In addition, HD-CTX plus C-HGF mobilization resulted in the appearance of greater numbers of PB colony-forming units - granulocyte/macrophage, -granulocyte/erythroid/macrophage/megakaryocyte, and -megakaryocyte (CFU-GM, CFU-GEMM, and CFU-Mk), and burst-forming units-erythroid and megakaryocyte (BFU-E and BFU-Mk) than those observed in the PB of group B patients (p <0.01). CD34+HLA-DR- cells isolated from the PB of group A patients were capable of initiating long-term hematopoiesis in vitro, which persisted for 10 weeks, while CD34+HLA-DR- cells obtained from the PB of group B patients were capable of sustaining long-term hematopoiesis in vitro for only 4 weeks. As determined by a limiting dilution analysis of group A PB CD34+HLA-DR- cells, the frequency of cells capable of giving rise to hematopoietic progenitor cells (pre-CFC) after 2 weeks in liquid culture was 4.3% (range 1.0-8.3%). Pre-CFC constituted 0.01% (range 0.001-0.02%) of group A PB mononuclear cells, and 151 pre-CFC were calculated to be present in 1 mL mobilized PB (range 20-310/mL). These results suggest that peripheral blood mononuclear cells (PBMC) collected by leukapheresis following HD-CTX plus C-HGF mobilization contain not only differentiated HPC but also more primitive HPC.

AB - In this report, we assess the content of primitive hematopoietic progenitor cells (HPC) that circulate transiently in the peripheral blood (PB) of cancer patients (group A) who received a PB stem-cell-mobilizing regimen that included high-dose chemotherapy (HD-CTX) of 7 g/m2 cyclophosphamide followed by a combination of recombinant hematopoietic growth factors (C-HGF), including either interleukin-3 (IL-3) plus granulocyte-colony stimulating factor (G-CSF), IL-3 plus granulocyte-macrophage colony-stimulating factor (GM-CSF), or a recombinant GM-CSF/IL-3 fusion protein (PIXY-321). These data were compared to the HPC content of PB obtained from a similar group of cancer patients that had not received such a mobilization regimen (group B). Monoclonal antibody staining and fluorescence-activated cell sorting (FACS) were used to identify and isolate cell populations enriched for more differentiated HPC (CD34+HLA-DR+) and more primitive HPC (CD34+HLA-DR-). The content of CD34+HLA-DR+ and CD34+HLA-DR- cells in the PB of group A patients was significantly greater than that observed in the PB of group B patients. In addition, HD-CTX plus C-HGF mobilization resulted in the appearance of greater numbers of PB colony-forming units - granulocyte/macrophage, -granulocyte/erythroid/macrophage/megakaryocyte, and -megakaryocyte (CFU-GM, CFU-GEMM, and CFU-Mk), and burst-forming units-erythroid and megakaryocyte (BFU-E and BFU-Mk) than those observed in the PB of group B patients (p <0.01). CD34+HLA-DR- cells isolated from the PB of group A patients were capable of initiating long-term hematopoiesis in vitro, which persisted for 10 weeks, while CD34+HLA-DR- cells obtained from the PB of group B patients were capable of sustaining long-term hematopoiesis in vitro for only 4 weeks. As determined by a limiting dilution analysis of group A PB CD34+HLA-DR- cells, the frequency of cells capable of giving rise to hematopoietic progenitor cells (pre-CFC) after 2 weeks in liquid culture was 4.3% (range 1.0-8.3%). Pre-CFC constituted 0.01% (range 0.001-0.02%) of group A PB mononuclear cells, and 151 pre-CFC were calculated to be present in 1 mL mobilized PB (range 20-310/mL). These results suggest that peripheral blood mononuclear cells (PBMC) collected by leukapheresis following HD-CTX plus C-HGF mobilization contain not only differentiated HPC but also more primitive HPC.

KW - Hematopoietic stem cells

KW - Peripheral blood grafts

UR - http://www.scopus.com/inward/record.url?scp=0027954071&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027954071&partnerID=8YFLogxK

M3 - Article

VL - 22

SP - 1016

EP - 1024

JO - Experimental Hematology

JF - Experimental Hematology

SN - 0301-472X

IS - 10

ER -